Tools for
Tomorrow's Therapies

Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced that it has entered into a definitive agreement whereby BioLife Solutions (NASDAQ: BLFS) will acquire all outstanding shares of...

Chimeric Antigen Receptor T cell (carT) Therapies have shown incredible efficacy against multiple hematological cancers. At present, the majority of both commercially available products and those in clinical trials are autologous by nature. Given the inherent...

Our second installment of a three-part series that examines the challenges in cell and gene manufacturing and how to overcome...